Budget 2025: FM to introduce additional tax slab of 25% for annual income of Rs 25-30 lakh?

With the Union Budget 2025 just around the corner, Finance Minister Nirmala Sitharaman has a big challenge to meet the growing expectations of various quarters, including taxpayers. From the government’s point of view, the challenge of handling taxpayers’ expectations has become more complex since 2020, when FM Sitharaman decided to introduce the new tax regime and also continue the old tax regime. With two systems in place, around 6.5 crore income tax filers out of the total of around 9 crore have switched to the new tax regime, and about 2.5 crore individuals are still under the old tax regime.

Similarly, with two distinct options available, taxpayers are also facing challenges in terms of dealing with the intricacies of the two tax systems.

CA (Dr.) Suresh Surana, a seasoned expert in taxation, highlights the complexities of the current system and suggests measures to simplify and rationalise individual taxation. Here’s a closer look at the key issues and recommendations for a unified tax system.

Also read: Budget 2025: Will FM take THESE bold decisions on insurance to benefit middle class? Check insurers’ wishlist!

Challenges in the existing dual tax regime: Complexity in tax computation

The current dual tax regime — offering taxpayers a choice between the old tax regime with deductions and exemptions and the new default tax regime with concessional rates but limited deductions — has introduced significant complexity, according to Surana. “Most individual taxpayers, especially salaried individuals, compute their tax liability on their own. Without professional assistance, it becomes difficult for them to assess and choose the most favorable tax regime,” he said.

Rigidity in switching between regimes

While taxpayers can choose between the two regimes each year, those earning income from business or profession face limitations. Surana points out, “A taxpayer deriving income from business or profession who opts out of the new tax regime under Section 115BAC can revert to it only once, making the process less flexible.”

Limited adoption of the new regime

Despite its goal of simplifying taxation and being the default choice since Finance Act 2023, the new tax regime has not gained widespread acceptance. “The restrictions on claiming deductions, such as health insurance premiums and standard deductions for salaried individuals, make the old tax regime more appealing for many taxpayers,” says Surana.

Also read: Old Tax Regime to see some changes finally?

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth